A new class of lipid-lowering drugs, inhibitors of PCSK9 has been generating 
impressive clinical trial data over the last several years, and alirocumab 
(Praluent) has become the first to be approved by the US FDA. Alirocumab has 
been shown to lower low density lipoprotein cholesterol by 45-62% with a safety 
profile generally comparable to placebo. Alirocumab is a monoclonal antibody to 
PCSK9 administered subcutaneously and has been evaluated in 16 Phase III 
clinical trials, the majority of which have been enrolled or completed. This 
article will be a review of the available Phase III safety and efficacy data of 
the ODYSSEY studies including a brief description of each of the 16 studies.